Drugs Made In America Acquisition (DMAA) Competitors $10.26 -0.01 (-0.10%) As of 08/5/2025 10:58 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOwnershipSEC FilingsTrendsBuy This Stock DMAA vs. USAR, SAFE, DEA, SBR, CSR, ORC, PAX, FBRT, NOAH, and NXRTShould you be buying Drugs Made In America Acquisition stock or one of its competitors? The main competitors of Drugs Made In America Acquisition include USA Rare Earth (USAR), Safehold (SAFE), Easterly Government Properties (DEA), Sabine Royalty Trust (SBR), Centerspace (CSR), Orchid Island Capital (ORC), Patria Investments (PAX), Franklin BSP Realty Trust (FBRT), Noah (NOAH), and NexPoint Residential Trust (NXRT). These companies are all part of the "trading" industry. Drugs Made In America Acquisition vs. Its Competitors USA Rare Earth Safehold Easterly Government Properties Sabine Royalty Trust Centerspace Orchid Island Capital Patria Investments Franklin BSP Realty Trust Noah NexPoint Residential Trust USA Rare Earth (NASDAQ:USAR) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Do analysts prefer USAR or DMAA? USA Rare Earth currently has a consensus price target of $16.00, suggesting a potential upside of 13.23%. Given USA Rare Earth's stronger consensus rating and higher possible upside, equities analysts plainly believe USA Rare Earth is more favorable than Drugs Made In America Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score USA Rare Earth 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Drugs Made In America Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is USAR or DMAA more profitable? Drugs Made In America Acquisition's return on equity of 0.00% beat USA Rare Earth's return on equity.Company Net Margins Return on Equity Return on Assets USA Rare EarthN/A -16.58% 2.58% Drugs Made In America Acquisition N/A N/A N/A Which has stronger earnings & valuation, USAR or DMAA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUSA Rare EarthN/AN/A$7.90MN/AN/ADrugs Made In America AcquisitionN/AN/AN/AN/AN/A Does the media refer more to USAR or DMAA? In the previous week, USA Rare Earth had 12 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 12 mentions for USA Rare Earth and 0 mentions for Drugs Made In America Acquisition. USA Rare Earth's average media sentiment score of 0.55 beat Drugs Made In America Acquisition's score of 0.00 indicating that USA Rare Earth is being referred to more favorably in the media. Company Overall Sentiment USA Rare Earth Positive Drugs Made In America Acquisition Neutral SummaryUSA Rare Earth beats Drugs Made In America Acquisition on 6 of the 7 factors compared between the two stocks. Get Drugs Made In America Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAA vs. The Competition Export to ExcelMetricDrugs Made In America AcquisitionInvestment Offices IndustryFinancial SectorNASDAQ ExchangeMarket Cap$299.59M$179.02M$6.34B$9.53BDividend YieldN/AN/A4.18%4.14%P/E RatioN/AN/A14.1223.88Price / SalesN/AN/A1,860.4198.82Price / CashN/A36,784.79127.2658.35Price / BookN/AN/A2.275.60Net IncomeN/A-$160K$1.23B$265.26M7 Day Performance-0.10%-0.43%0.33%-0.14%1 Month PerformanceN/A0.46%8.99%6.08%1 Year PerformanceN/A6.54%22.95%24.22% Drugs Made In America Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMAADrugs Made In America AcquisitionN/A$10.26-0.1%N/AN/A$299.59MN/A0.002High Trading VolumeUSARUSA Rare EarthN/A$12.71+14.0%$16.00+25.9%N/A$1.15BN/A0.00N/AOptions VolumeHigh Trading VolumeSAFESafehold4.1847 of 5 stars$13.99-0.7%$22.33+59.6%-36.8%$1.00B$370.15M9.58120News CoverageEarnings ReportDEAEasterly Government Properties2.7261 of 5 stars$22.00-0.7%$27.15+23.4%-32.8%$987.58M$302.05M52.3750News CoverageEarnings ReportDividend CutSBRSabine Royalty Trust1.4782 of 5 stars$66.36-0.3%N/A+13.2%$967.46M$81.21M12.452,020News CoveragePositive NewsCSRCenterspace3.7578 of 5 stars$54.45-2.3%$70.78+30.0%-20.5%$911.49M$260.98M-48.62470Trending NewsEarnings ReportGap UpORCOrchid Island Capital2.8234 of 5 stars$6.96-2.7%N/A-7.2%$881.40M$24.26M34.782,018PAXPatria Investments3.3104 of 5 stars$13.95-1.1%$14.00+0.4%+26.2%$845.94M$390.10M27.90390FBRTFranklin BSP Realty Trust3.6834 of 5 stars$10.09+0.1%$15.13+49.8%-12.3%$829.83M$210.45M14.84N/APositive NewsHigh Trading VolumeNOAHNoah3.1259 of 5 stars$12.15-0.2%$12.00-1.2%+60.7%$803.80M$2.57B12.531,990NXRTNexPoint Residential Trust4.6411 of 5 stars$31.17-5.5%$43.58+39.8%-26.4%$788.13M$250.56M-15.903High Trading Volume Related Companies and Tools Related Companies USAR Alternatives SAFE Alternatives DEA Alternatives SBR Alternatives CSR Alternatives ORC Alternatives PAX Alternatives FBRT Alternatives NOAH Alternatives NXRT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Drugs Made In America Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Drugs Made In America Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
